AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
Rivalry Corp. Receives Management Cease Trade Order for Q1 2025 Annual Filings
ByAinvest
Friday, May 2, 2025 6:01 am ET1min read
Rivalry Corp, a leading sportsbook and iGaming operator, has been granted a Management Cease Trade Order due to its inability to file annual financial statements on time. The company has until June 30, 2025 to file the statements and will comply with guidelines set out in National Policy 12-203. Rivalry has also secured a $600,000 senior unsecured loan from its existing senior lender, maturing on September 30, 2025, with an interest rate of 10% per annum.
VANCOUVER, BC / ACCESS Newswire / May 2, 2025 / Rivalry Corp (CSE:RIV), a leading sportsbook and iGaming operator, has been granted a Management Cease Trade Order (MCTO) due to its inability to file its annual financial statements by the deadline. The company has until June 30, 2025, to comply with the order and will adhere to the guidelines set out in National Policy 12-203 [1].Rivalry Corp has secured a $600,000 senior unsecured loan from its existing senior lender, maturing on September 30, 2025, with an interest rate of 10% per annum. This loan is intended to help the company meet its financial obligations and complete the required filings.
The MCTO restricts the Chief Executive Officer (CEO) and Chief Financial Officer (CFO) from trading the company's securities until the annual financial statements and related management's discussion and analysis are filed. The company has confirmed that there is no other material information relating to its affairs that has not been generally disclosed.
Rivalry Corp operates in the competitive sportsbook and iGaming industry, focusing on delivering a wide range of betting options and innovative gaming experiences. The company is listed on the Canadian Securities Exchange and is committed to maintaining transparency and compliance with regulatory requirements.
References:
[1] https://www.tradingview.com/news/reuters.com,2025-05-01:newsml_Tnw82fZ4W:0-pangenomic-health-announces-issuance-of-management-cease-trade-order-for-late-filing-of-audited-annual-financial-statements/
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet